Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4827895 | 0.99 | KMT2A (0.54) | KMT2ACNR1SIGMAR1HRH1HRH4 | |
| SCHEMBL6378898 | 0.83 | KMT2A (0.51) | KMT2ACNR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4830942 | 0.83 | KMT2A (0.50) | KMT2ACNR1ALDH1A1 | |
| SCHEMBL4836256 | 0.81 | KMT2A (0.48) | KMT2ACNR1HRH1HRH4HRH3 | |
| SCHEMBL6379108 | 0.81 | KMT2A (0.48) | KMT2ACNR1ALDH1A1 | |
| SCHEMBL4831071 | 0.81 | KMT2A (0.48) | KMT2ACNR1HRH1HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL4836804 | 0.80 | KMT2A (0.47) | KMT2ACNR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4827786 | 0.80 | KMT2A (0.47) | KMT2ACNR1HRH1HRH4HRH3 | |
| SCHEMBL6409073 | 0.80 | CCR3 (0.50) | KMT2ASIGMAR1MEN1CCR3 | |
| Hydrochloric Acid SCHEMBL6410465 | 0.79 | CCR3 (0.49) | KMT2ASIGMAR1MEN1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-04-07 | — | — | US | claimed |
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | disclosed |
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | KMT2A 4243/4885CNR1 60/4885SIGMAR1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.